The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy
Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baselin...
Published in: | Arthritis Research & Therapy |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/1956/19878 https://doi.org/10.1186/s13075-018-1635-7 |
id |
ftunivbergen:oai:bora.uib.no:1956/19878 |
---|---|
record_format |
openpolar |
spelling |
ftunivbergen:oai:bora.uib.no:1956/19878 2023-05-15T15:16:49+02:00 The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. 2019-03-20T07:47:50Z application/pdf https://hdl.handle.net/1956/19878 https://doi.org/10.1186/s13075-018-1635-7 eng eng BioMed Central urn:issn:1478-6362 https://hdl.handle.net/1956/19878 https://doi.org/10.1186/s13075-018-1635-7 cristin:1603450 Attribution CC BY http://creativecommons.org/licenses/by/4.0 Copyright 2018 The Author(s) Arthritis Research & Therapy Rheumatoid arthritis Biomarkers Inflammation Imaging Outcomes Peer reviewed Journal article 2019 ftunivbergen https://doi.org/10.1186/s13075-018-1635-7 2023-03-14T17:43:45Z Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception cohort of patients with early RA, and to investigate their associations with disease activity, treatment response, ultrasound findings and radiographic damage. Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone bridging. Analysis of 16 different ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, filaggrin and histone was performed using a multiplex chip-based assay. Samples from 0, 3, 12 and 24 months were analysed. Controls were blood donors with similar characteristics to the patients (age, gender, smoking status). Results: A total of 217 patients and 94 controls were included. Median [25, 75 percentile] number of ACPA reactivities in all patients was 9 [4, 12], and were most prevalent in anti-cyclic citrullinated peptide /rheumatoid factor-positive patients 10 [7, 12]. Disease activity measures and ultrasound scores at baseline were lower in ACPA reactivity-positive compared to ACPA reactivity-negative patients. ACPA reactivity levels decreased after 3 months of DMARD treatment, most pronounced for fibrinogenβ 60–74 to 62% of baseline antibody level, with least change in filaggrin 307–324 to 81% of baseline antibody level, both p < 0.001. However, outcomes in disease activity measures, ultrasound and radiographic scores after 12 and 24 ... Article in Journal/Newspaper Arctic University of Bergen: Bergen Open Research Archive (BORA-UiB) Arctic Arthritis Research & Therapy 20 1 |
institution |
Open Polar |
collection |
University of Bergen: Bergen Open Research Archive (BORA-UiB) |
op_collection_id |
ftunivbergen |
language |
English |
topic |
Rheumatoid arthritis Biomarkers Inflammation Imaging Outcomes |
spellingShingle |
Rheumatoid arthritis Biomarkers Inflammation Imaging Outcomes Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
topic_facet |
Rheumatoid arthritis Biomarkers Inflammation Imaging Outcomes |
description |
Background: Anti-citrullinated protein antibody (ACPA) reactivities precede clinical onset of rheumatoid arthritis (RA), and it has been suggested that ACPA reactivities towards distinct target proteins may be associated with differences in RA phenotypes. We aimed to assess the prevalence of baseline ACPA reactivities in an inception cohort of patients with early RA, and to investigate their associations with disease activity, treatment response, ultrasound findings and radiographic damage. Methods: Disease-modifying antirheumatic drug (DMARD)-naïve patients with early RA, classified according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, were included in the ARCTIC trial and assessed in the present analysis. During follow up, patients were monitored frequently and treatment was adjusted according to a predetermined protocol, starting with methotrexate monotherapy with prednisolone bridging. Analysis of 16 different ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, filaggrin and histone was performed using a multiplex chip-based assay. Samples from 0, 3, 12 and 24 months were analysed. Controls were blood donors with similar characteristics to the patients (age, gender, smoking status). Results: A total of 217 patients and 94 controls were included. Median [25, 75 percentile] number of ACPA reactivities in all patients was 9 [4, 12], and were most prevalent in anti-cyclic citrullinated peptide /rheumatoid factor-positive patients 10 [7, 12]. Disease activity measures and ultrasound scores at baseline were lower in ACPA reactivity-positive compared to ACPA reactivity-negative patients. ACPA reactivity levels decreased after 3 months of DMARD treatment, most pronounced for fibrinogenβ 60–74 to 62% of baseline antibody level, with least change in filaggrin 307–324 to 81% of baseline antibody level, both p < 0.001. However, outcomes in disease activity measures, ultrasound and radiographic scores after 12 and 24 ... |
format |
Article in Journal/Newspaper |
author |
Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. |
author_facet |
Jonsson, Maria Karolina Hensvold, Aase Haj Hansson, Monika Aga, Anna-Birgitte Sexton, Joseph Mathsson-Alm, Linda Cornillet, Martin Serre, Guy Lillegraven, Siri Fevang, Bjørg-Tilde Svanes Catrina, Anca Irinel Haavardsholm, Espen A. |
author_sort |
Jonsson, Maria Karolina |
title |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_short |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_full |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_fullStr |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_full_unstemmed |
The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
title_sort |
role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy |
publisher |
BioMed Central |
publishDate |
2019 |
url |
https://hdl.handle.net/1956/19878 https://doi.org/10.1186/s13075-018-1635-7 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Arthritis Research & Therapy |
op_relation |
urn:issn:1478-6362 https://hdl.handle.net/1956/19878 https://doi.org/10.1186/s13075-018-1635-7 cristin:1603450 |
op_rights |
Attribution CC BY http://creativecommons.org/licenses/by/4.0 Copyright 2018 The Author(s) |
op_doi |
https://doi.org/10.1186/s13075-018-1635-7 |
container_title |
Arthritis Research & Therapy |
container_volume |
20 |
container_issue |
1 |
_version_ |
1766347110020546560 |